4578 (4578) News
Follow 4578 (4578) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: Wholly owned drug sales shift and Rezilient3 6-month PFS
Jefferies raised its target to ¥14,000 as Otsuka Holdings Co., Ltd. (TSE:4578) shifts sales toward wholly owned drugs like Voyxact, with shares at ¥11,770, while Rezilient3’s Phase 3 data show zipalertinib plus chemo del
EQUITY | Sep 14, 2026, 10:15 PM UTC
L
Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Otsuka Holdings Co., Ltd. TSE:4578
NEWS | Sep 13, 2026, 11:36 PM UTC
M
Jefferies says Otsuka’s wholly owned products mix may lift margins
Jefferies analysts said Otsuka Holdings’ revenue growth from wholly owned products is likely to help boost profitability, citing an improving product mix and margin impact. Consensus may be underestimating the effect.
EQUITY | Sep 08, 2026, 04:42 AM UTC